BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26349984)

  • 1. MicroRNA-induced drug resistance in gastric cancer.
    Dehghanzadeh R; Jadidi-Niaragh F; Gharibi T; Yousefi M
    Biomed Pharmacother; 2015 Aug; 74():191-9. PubMed ID: 26349984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Role of miRNAs in the Drug Resistance of Gastric Cancer.
    Riquelme I; Letelier P; Riffo-Campos AL; Brebi P; Roa JC
    Int J Mol Sci; 2016 Mar; 17(3):424. PubMed ID: 27011182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms and theranostic potential of miRNAs in drug resistance of gastric cancer.
    Yang W; Ma J; Zhou W; Cao B; Zhou X; Yang Z; Zhang H; Zhao Q; Fan D; Hong L
    Expert Opin Ther Targets; 2017 Nov; 21(11):1063-1075. PubMed ID: 28994330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Roles of microRNAs in Multidrug-Resistance Mechanisms in Gastric Cancer.
    Zeng X; Wang HY; Bai SY; Pu K; Wang YP; Zhou YN
    Curr Mol Med; 2020; 20(9):667-674. PubMed ID: 32209033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of microRNA in anticancer drug resistance.
    Zheng T; Wang J; Chen X; Liu L
    Int J Cancer; 2010 Jan; 126(1):2-10. PubMed ID: 19634138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling.
    Chen Z; Zhang L; Xia L; Jin Y; Wu Q; Guo H; Shang X; Dou J; Wu K; Nie Y; Fan D
    Cancer Lett; 2014 Aug; 350(1-2):43-51. PubMed ID: 24759738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction/reversal of drug resistance in gastric cancer by non-coding RNAs (Review).
    Chen C; Tang X; Liu Y; Zhu J; Liu J
    Int J Oncol; 2019 May; 54(5):1511-1524. PubMed ID: 30896792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting miR-375 in gastric cancer.
    Xu Y; Deng Y; Yan X; Zhou T
    Expert Opin Ther Targets; 2011 Aug; 15(8):961-72. PubMed ID: 21557705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the production of oncogenic microRNAs with multimodal synthetic small molecules.
    Vo DD; Staedel C; Zehnacker L; Benhida R; Darfeuille F; Duca M
    ACS Chem Biol; 2014 Mar; 9(3):711-21. PubMed ID: 24359019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current perspectives toward the identification of key players in gastric cancer microRNA dysregulation.
    Ishimoto T; Baba H; Izumi D; Sugihara H; Kurashige J; Iwatsuki M; Tan P
    Int J Cancer; 2016 Mar; 138(6):1337-49. PubMed ID: 26041092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.
    Giovannetti E; Erozenci A; Smit J; Danesi R; Peters GJ
    Crit Rev Oncol Hematol; 2012 Feb; 81(2):103-22. PubMed ID: 21546262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNAs and cancer resistance: A new molecular plot.
    Fanini F; Fabbri M
    Clin Pharmacol Ther; 2016 May; 99(5):485-93. PubMed ID: 26875151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noncoding RNAs in gastric cancer: implications for drug resistance.
    Wei L; Sun J; Zhang N; Zheng Y; Wang X; Lv L; Liu J; Xu Y; Shen Y; Yang M
    Mol Cancer; 2020 Mar; 19(1):62. PubMed ID: 32192494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNAs: promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential.
    Matuszcak C; Haier J; Hummel R; Lindner K
    World J Gastroenterol; 2014 Oct; 20(38):13658-66. PubMed ID: 25320504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA and drug resistance.
    Ma J; Dong C; Ji C
    Cancer Gene Ther; 2010 Aug; 17(8):523-31. PubMed ID: 20467450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms and clinical implications of miRNAs in drug resistance of esophageal cancer.
    Yang W; Ma J; Zhou W; Zhou X; Cao B; Zhang H; Zhao Q; Fan D; Hong L
    Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1151-1163. PubMed ID: 28838272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNAs in gastric cancer: Biomarkers and therapeutic targets.
    Ghafouri-Fard S; Vafaee R; Shoorei H; Taheri M
    Gene; 2020 Oct; 757():144937. PubMed ID: 32640300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced HER2-positive gastric cancer: current and future targeted therapies.
    Pazo Cid RA; Antón A
    Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers.
    Dai X; Tan C
    Adv Drug Deliv Rev; 2015 Jan; 81():184-97. PubMed ID: 25281917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3.
    Zhang Y; Lu Q; Cai X
    FEBS Lett; 2013 Sep; 587(18):3069-75. PubMed ID: 23932924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.